Association and Predictive Value of Sarcopenic Obesity for the Prognosis of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Why It Matters

SO markedly worsens survival for ICI‑treated lung cancer, highlighting a modifiable risk factor that can refine patient stratification and therapeutic planning.

Key Takeaways

• Sarcopenic obesity reduces 3‑year survival in ICI‑treated lung cancer
• SO hazard ratio 3.48, independent of other clinical factors
• Later‑line ICI therapy and ECOG‑PS ≥3 also worsen outcomes
• Creatinine inversely correlates with mortality, reflecting muscle mass loss
• Early CT‑based body composition assessment can guide nutritional interventions

Pulse Analysis

Immune checkpoint inhibitors have reshaped the therapeutic landscape for advanced lung cancer, yet response heterogeneity remains a critical challenge. Emerging evidence points to host factors—particularly body composition—as decisive determinants of immunotherapy efficacy. While obesity alone has produced mixed signals, the coexistence of reduced skeletal muscle mass and excess adiposity, termed sarcopenic obesity, creates a unique metabolic milieu that can blunt immune activation and accelerate tumor progression.

The recent Chinese cohort study underscores this risk, revealing that patients classified with sarcopenic obesity faced a median overall survival of just 22.5 months, compared with nearly 30 months for controls. After adjusting for age, stage, and laboratory markers, SO retained a hazard ratio of 3.48, eclipsing the prognostic impact of sarcopenia or obesity in isolation. Mechanistically, sarcopenia diminishes muscle‑derived cytokines essential for T‑cell maintenance, while excess visceral fat fuels chronic inflammation, together impairing the anti‑tumor immune response that ICIs rely upon.

Clinically, these findings argue for integrating CT‑derived muscle and fat metrics into routine oncology workflows. Early identification of SO enables targeted nutritional counseling, resistance‑training programs, and possibly adjunctive pharmacologic strategies to restore muscle mass before or during immunotherapy. Prospective, multi‑center trials are needed to validate whether such interventions can translate into measurable survival gains, but the current data already suggest that body‑composition profiling should become a standard component of precision oncology for lung cancer patients receiving checkpoint blockade.